<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04502771</url>
  </required_header>
  <id_info>
    <org_study_id>CRC_GHN_2020_003</org_study_id>
    <nct_id>NCT04502771</nct_id>
  </id_info>
  <brief_title>Therapeutic Drug Monitoring of Antifungals in Intensive Care Units</brief_title>
  <acronym>Fungi-up</acronym>
  <official_title>Therapeutic Drug Monitoring of Antifungals in Patients From Intensive Care Units: a Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antifungals under- and over-dosing are frequently deplored in patients treated with&#xD;
      antifungals and receiving recommended doses, mostly in critically-ill patients. This&#xD;
      situation is well-described for antifungals from the azoles class mostly in patients with&#xD;
      liver dysfunction or having concomitant drugs that may interact with azoles. This situation&#xD;
      is less-described using echinocandins, although recent studies reported caspofungin&#xD;
      underdosing for critically-ill patients. Considering that antifungals under-dosing was&#xD;
      demonstrated to be associated with an increase in mortality, it is of utmost importance to&#xD;
      analyse the relevance of therapeutic drug monitoring (TDM) for patients admitted in intensive&#xD;
      care units (ICU). This will help to identify which patients are the more prone to antifungal&#xD;
      under or over-dosing. Indeed, antifungals under-dosing may favour the development of clinical&#xD;
      resistance to antifungals and increase mortality, whereas over-dosing may result in adverse&#xD;
      events that may lead to treatment discontinuation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Antifungal blood concentration of patients admitted in intensive care units</measure>
    <time_frame>Day 5 after antifungal initiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>Day 30 after antifungal initiation</time_frame>
    <description>Impact of antifungal blood concentration on occurrence of adverse events and mycological failure</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">200</enrollment>
  <condition>Intensive Care Unit Patients</condition>
  <arm_group>
    <arm_group_label>Antifungal treatment</arm_group_label>
    <description>Patients receiving antifungal treatment during their stay in Intensive Care Unit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antifungal treatment</intervention_name>
    <description>Treatment by fluconazole, voriconazole,posaconazole or caspofungin during the patient stay in Intensive Care Unit</description>
    <arm_group_label>Antifungal treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who received antifungals during their ICU stay and had a TDM&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients who received antifungals including fluconazole, voriconazole,&#xD;
             posaconazole, or caspofungin, during their ICU stay and had a Therapeutic Drug&#xD;
             Monitoring (TDM)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients without antifungal treatment&#xD;
&#xD;
          -  Patients who received an antifungal combination&#xD;
&#xD;
          -  Pediatric patients&#xD;
&#xD;
          -  Patients who were not admitted in ICU&#xD;
&#xD;
          -  Patients who did not have a TDM&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospices Civils de Lyon, Croix-Rousse Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 4, 2020</study_first_submitted>
  <study_first_submitted_qc>August 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2020</study_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fluconazole</keyword>
  <keyword>Voriconazole</keyword>
  <keyword>Posaconazole</keyword>
  <keyword>Caspofungin</keyword>
  <keyword>Therapeutic drug monitoring</keyword>
  <keyword>Blood concentration</keyword>
  <keyword>Under-dosing</keyword>
  <keyword>Over-dosing</keyword>
  <keyword>Intensive Care Unit</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antifungal Agents</mesh_term>
    <mesh_term>Clotrimazole</mesh_term>
    <mesh_term>Miconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

